Valeo Financial Advisors, LLC Biocryst Pharmaceuticals Inc Transaction History

Valeo Financial Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$7.89 - $17.88 $3,945 - $8,940	-500 Reduced 1.82%	27,000 $286,000
Q1 2022 Apr 28, 2022	SELL	$11.56 - $19.76 $3,745 - $6,402	-324 Reduced 1.16%	27,500 $447,000
Q4 2021 Jan 07, 2022	SELL	$11.18 - $15.46 $5,590 - $7,730	-500 Reduced 1.77%	27,824 $385,000
Q2 2021 Jul 22, 2021	SELL	$9.5 - $17.24 $4,750 - $8,620	-500 Reduced 1.73%	28,324 $448,000
Q1 2021 Apr 12, 2021	SELL	$7.37 - $13.61 $61,731 - $113,997	-8,376 Reduced 22.52%	28,824 $293,000
Q4 2020 Feb 11, 2021	BUY	$3.37 - $8.61 $58,975 - $150,675	17,500 Added 88.83%	37,200 $277,000
Q3 2020 Oct 28, 2020	BUY	$3.43 - $5.53 $53,165 - $85,715	15,500 Added 369.05%	19,700 $68,000
Q2 2020 Jul 20, 2020	BUY	$1.9 - $5.61 $7,980 - $23,562	4,200 New	4,200 $20,000

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.45B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Valeo Financial Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Valeo Financial Advisors, LLC with notifications on news.